Armata Pharmaceuticals, Inc. has released its financial results for the third quarter of 2026, marking a significant period for the company as it continues to develop its portfolio of biological products. The results, filed on November 12, 2026, highlight the company's progress and ongoing commitment to innovation in the biotechnology sector.

As a company focused on biological products, Armata Pharmaceuticals operates under the Standard Industrial Classification (SIC) code 2836, which encompasses biological products excluding diagnostic substances. The firm trades under the ticker ARMP on the New York Stock Exchange (NYSE) and has been recognized as a smaller reporting company.

Background

Founded in Washington, Armata Pharmaceuticals has a mission to advance the development of innovative therapies in the biological products space. The company has undergone several transformations, previously known as AmpliPhi Biosciences Corp and Targeted Genetics Corp. Its recent filings indicate a proactive approach to research and development, aiming to address unmet medical needs.

What the Filing Says

In the recent 10-Q filing, Armata Pharmaceuticals reported key financial metrics and developments. The document outlines the company's financial performance for the quarter ending September 30, 2026. Specific figures regarding revenue, expenses, and net income were not detailed in the filing, but the company emphasized its focus on advancing its product pipeline.

Impact

The results from Armata Pharmaceuticals may significantly impact various stakeholders, including investors, healthcare professionals, and competitors in the biological products industry. The company's ongoing development efforts could influence market dynamics, particularly as it seeks to introduce new therapies and expand its market presence.

What's Next

The filing does not specify the next steps for Armata Pharmaceuticals, but it is expected that the company will continue to focus on advancing its product pipeline and may provide further updates in future filings.

For more information, the full filing can be accessed at the SEC's website under accession number 0001104659-26-126277.